NASDAQ:HSCS HeartSciences (HSCS) Stock Price, News & Analysis $3.47 +0.17 (+5.15%) Closing price 04:00 PM EasternExtended Trading$3.42 -0.05 (-1.30%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About HeartSciences Stock (NASDAQ:HSCS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get HeartSciences alerts:Sign Up Key Stats Today's Range$3.32▼$3.7050-Day Range$3.01▼$5.7352-Week Range$2.52▼$6.47Volume235,545 shsAverage Volume59,911 shsMarket Capitalization$9.20 millionP/E RatioN/ADividend YieldN/APrice Target$13.00Consensus RatingBuy Company Overview HeartSciences, Inc. (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems. HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows. The technology has received regulatory clearance in key markets including the United States and European Union, and the company continues to forge distribution partnerships and develop direct sales channels to broaden its reach among cardiology practices, hospitals and primary care providers. Concurrently, HeartSciences is advancing its research efforts to explore additional clinical applications and refine its diagnostic algorithms. Headquartered in Bothell, Washington, HeartSciences maintains research and development operations in the United States and collaborates with academic and clinical institutions to validate and expand its platform. As a publicly traded company on the NASDAQ exchange, HeartSciences is led by an executive team and governed by a board of directors committed to driving innovation in non‐invasive cardiovascular diagnostics. Through ongoing product development and strategic partnerships, the company aims to enhance patient outcomes and support clinicians with robust, data‐driven diagnostic tools.AI Generated. May Contain Errors. Read More HeartSciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreHSCS MarketRank™: HeartSciences scored higher than 58% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingHeartSciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Upside PotentialHeartSciences has a consensus price target of $13.00, representing about 274.6% upside from its current price of $3.47.Amount of Analyst CoverageHeartSciences has received no research coverage in the past 90 days.Read more about HeartSciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for HeartSciences are expected to grow in the coming year, from ($10.01) to ($8.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of HeartSciences is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of HeartSciences is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHeartSciences has a P/B Ratio of 19.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.20% of the float of HeartSciences has been sold short.Short Interest Ratio / Days to CoverHeartSciences has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in HeartSciences has recently decreased by 13.68%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHeartSciences does not currently pay a dividend.Dividend GrowthHeartSciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.20% of the float of HeartSciences has been sold short.Short Interest Ratio / Days to CoverHeartSciences has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in HeartSciences has recently decreased by 13.68%, indicating that investor sentiment is improving significantly. News and Social Media2.8 / 5News Sentiment0.98 News SentimentHeartSciences has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for HeartSciences this week, compared to 0 articles on an average week.Search InterestOnly 2 people have searched for HSCS on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows4 people have added HeartSciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, HeartSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,633.00 in company stock.Percentage Held by InsidersOnly 1.80% of the stock of HeartSciences is held by insiders.Percentage Held by InstitutionsOnly 17.24% of the stock of HeartSciences is held by institutions.Read more about HeartSciences' insider trading history. Receive HSCS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HeartSciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HSCS Stock News HeadlinesHeartSciences Inc.: HeartSciences Provides Business Update and Reports First Quarter of Fiscal 2026 Financial ResultsSeptember 12, 2025 | finanznachrichten.deHeartSciences Provides Business Update and Reports First Quarter of Fiscal 2026 Financial ResultsSeptember 11, 2025 | globenewswire.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.September 16 at 2:00 AM | Porter & Company (Ad)HeartSciences (HSCS) Projected to Post Earnings on ThursdaySeptember 9, 2025 | americanbankingnews.comHeartSciences Inc. Announces Participation in Virtual Events for Investor Engagement and Technology Update in August 2025August 15, 2025 | quiverquant.comQHeartSciences Announces Conference Participation and Investor WebinarAugust 15, 2025 | globenewswire.comHeartSciences Inc.: HeartSciences Provides Business Update and Reports Fiscal 2025 Financial ResultsJuly 25, 2025 | finanznachrichten.deHeartSciences Provides Business Update and Reports Fiscal 2025 Financial ResultsJuly 24, 2025 | globenewswire.comSee More Headlines HSCS Stock Analysis - Frequently Asked Questions How have HSCS shares performed this year? HeartSciences' stock was trading at $3.82 at the start of the year. Since then, HSCS stock has decreased by 9.2% and is now trading at $3.47. How were HeartSciences' earnings last quarter? HeartSciences Inc. (NASDAQ:HSCS) released its earnings results on Thursday, September, 11th. The company reported ($1.58) EPS for the quarter, topping the consensus estimate of ($2.41) by $0.83. When did HeartSciences' stock split? HeartSciences's stock reverse split on the morning of Friday, May 17th 2024.The 1-100 reverse split was announced on Friday, May 17th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. When did HeartSciences IPO? HeartSciences (HSCS) raised $9 million in an initial public offering on Wednesday, June 15th 2022. The company issued 1,800,000 shares at $4.50-$5.50 per share. The Benchmark Company acted as the underwriter for the IPO. Who are HeartSciences' major shareholders? Top institutional shareholders of HeartSciences include Geode Capital Management LLC (0.51%). View institutional ownership trends. How do I buy shares of HeartSciences? Shares of HSCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of HeartSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that HeartSciences investors own include Meta Platforms (META), Cardio Diagnostics (CDIO), Invesco QQQ (QQQ), RH (RH), Exxon Mobil (XOM), Amarin (AMRN) and American Express (AXP). Company Calendar Last Earnings9/11/2025Today9/16/2025Fiscal Year End4/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MEDICAL INFO SYS Sub-IndustryMedical Equipment Current SymbolNASDAQ:HSCS CIK1468492 Webheartsciences.com Phone682-237-7781FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Price Target for HeartSciences$13.00 High Price Target$14.00 Low Price Target$12.00 Potential Upside/Downside+283.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($8.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.77 million Net MarginsN/A Pretax Margin-146,133.33% Return on Equity-383.38% Return on Assets-145.28% Debt Debt-to-Equity RatioN/A Current Ratio1.47 Quick Ratio1.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.18 per share Price / Book18.83Miscellaneous Outstanding Shares2,650,000Free Float2,600,000Market Cap$8.98 million OptionableNot Optionable Beta2.56 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:HSCS) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersFanatics Hit $31B-Is This Nasdaq Next?Fanatics built an empire by owning the fan experience-scaling to a $31B valuation. But the next wave isn't abo...i2i Marketing Group, LLC | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HeartSciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HeartSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.